华润双鹤(600062.SH)控股子公司双鹤天安通过GMP符合性检查

Core Viewpoint - China Resources Double Crane Pharmaceutical (华润双鹤) announced that its subsidiary, Double Crane Tianan Pharmaceutical (贵州双鹤天安药业), received a GMP compliance inspection notice from the Guizhou Provincial Drug Administration, indicating regulatory approval for its production line [1] Group 1: Company Information - The subsidiary involved is Double Crane Tianan Pharmaceutical, which is located in Guizhou [1] - The production line is designed for the manufacturing of Metformin and Ertugliflozin tablets, with a capacity of 500 million tablets per year [1] Group 2: Regulatory Approval - The notice received is titled "Drug GMP Compliance Inspection Notice" with the reference number: 黔20250059 [1] - The inspection covered the tablet production line and related workshops, confirming compliance with GMP standards [1]